PhaseBio Pharmaceuticals

CompanyUnited States

PhaseBio Pharmaceuticals develops 3 assets, the furthest in phase 3 (bentracimab in hemorrhage). Mostly antibody and protein or enzyme acting on CYP11B2; based in the United States.

3
Assets
Furthest stage
Phase 3
Raised
$95.5M
2
Trials
0
Signals

Pipeline

3
  • bentracimab

    Binds ticagrelor and its active metabolite to reverse antiplatelet activity.

    Phase 3, Antibody, hemorrhage, invasive procedure

  • Glymera

    Long-acting GLP-1 receptor agonist fusion protein that stimulates glucose-dependent insulin secretion and improves glycemic control.

    Phase 2, no development reported, Protein or enzyme, type 2 diabetes

  • PB6440

    Selectively inhibits aldosterone synthase to reduce aldosterone production and lower blood pressure.

    Preclinical, no development reported, Small molecule, CYP11B2, treatment-resistant hypertension

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials2
  • Funding rounds and grants3
  • Deals10
  • Similar companies6

Intelligence